| __timestamp | Blueprint Medicines Corporation | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 54170000 |
| Thursday, January 1, 2015 | 14456000 | 65378000 |
| Friday, January 1, 2016 | 19218000 | 52263000 |
| Sunday, January 1, 2017 | 27986000 | 35072000 |
| Monday, January 1, 2018 | 47928000 | 27415000 |
| Tuesday, January 1, 2019 | 96388000 | 36983000 |
| Wednesday, January 1, 2020 | 157743000 | 50918000 |
| Friday, January 1, 2021 | 195293000 | 63586000 |
| Saturday, January 1, 2022 | 237374000 | 57967000 |
| Sunday, January 1, 2023 | 295141000 | 53107000 |
| Monday, January 1, 2024 | 359272000 | 23626000 |
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Mesoblast Limited from 2014 to 2023. Blueprint Medicines has seen a dramatic increase in SG&A expenses, rising from approximately $7.9 million in 2014 to nearly $295 million in 2023, reflecting a growth of over 3,600%. This surge indicates aggressive expansion and investment in operational capabilities. In contrast, Mesoblast Limited's SG&A expenses have remained relatively stable, peaking at around $65 million in 2015 and maintaining an average of $47 million over the years. This stability suggests a more conservative approach to cost management. The data for 2024 is incomplete, highlighting the need for ongoing analysis to understand future trends. This comparison offers valuable insights into the strategic priorities of these two biotech firms.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Who Prioritizes Innovation? R&D Spending Compared for Blueprint Medicines Corporation and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Breaking Down SG&A Expenses: Mesoblast Limited vs Galapagos NV